Latest X-BODY BioSciences Stories

2014-03-31 08:31:02

SAN FRANCISCO and WALTHAM, Mass., March 31, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and Kindred Bio will develop and commercialize these antibodies. Kindred Bio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these...

2010-11-30 07:00:00

WALTHAM, Mass., Nov. 30, 2010 /PRNewswire/ -- X-BODY Biosciences, a developer of monoclonal antibody therapeutics, today announced the launch of its Protein Chain Reaction(TM) antibody discovery platform. The company will give its first public presentations at IBC's 21st Annual International Conference on Antibody Engineering held December 5-9th in San Diego. Richard Wagner, Ph.D., Co-Founder and Executive Chairman of X-BODY will present a talk entitled, "Discovery and Characterization of...

2010-11-01 17:57:00

WALTHAM, Mass., Nov. 1, 2010 /PRNewswire/ -- X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, today announced it has been awarded a research grant under the Patient Protection and Affordable Care Act of 2010 for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells. The grant was awarded by the US Department of the Treasury and reviewed by scientists at the Department of Health and Human Services. This grant provides X-BODY with...

Word of the Day
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.